Company Overview - Heartflow, Inc. is a leader in AI technology for coronary artery disease (CAD) [1] - The company is advancing coronary care by transforming CAD into a screenable, diagnosable, and manageable condition [3] - Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway [3] - The AI-driven platform includes Roadmap™ Analysis, FFRCT Analysis, and Plaque Analysis, supported by the ACC/AHA Chest Pain Guideline and backed by over 600 peer-reviewed publications [3] - Heartflow has assisted clinicians in managing over 400,000 patients worldwide [3] Upcoming Events - Members of Heartflow management will participate in a fireside chat at the Morgan Stanley 23 Annual Global Healthcare Conference on September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET [1] - A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website [2]

Core Viewpoint - Sanara MedTech Inc. is set to present at the Cantor Global Healthcare Conference, highlighting its focus on developing transformative medical technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical and wound care markets [1][2]. Company Overview - Sanara MedTech Inc. specializes in medical technology, particularly in surgical, chronic wound, and skin markets, with a commitment to enhancing clinical outcomes and minimizing healthcare expenditures [3]. - The company markets and distributes a range of products, including CellerateRX Surgical Activated Collagen and FORTIFY TRG Tissue Repair Graft, primarily in the North American advanced wound care and surgical tissue repair markets [3]. - Sanara's product portfolio includes advanced biologic products such as ACTIGEN™ Verified Inductive Bone Matrix and BIASURGE Advanced Surgical Solution, along with wound care products like BIAKŌS Antimicrobial Skin and Wound Cleanser [3]. - The company is actively pursuing long-term strategic partnerships to develop products that improve patient outcomes while reducing overall costs [3]. Upcoming Events - Management will participate in a fireside chat presentation at the Cantor Global Healthcare Conference on September 3, 2025, at approximately 2:45 p.m. Eastern Time [1]. - Presentation materials will be available on the company's investor relations website prior to the event, along with a live audio webcast and an archive for replay after the conference [2].

Core Insights - The study published in The Lancet Respiratory Medicine indicates a significant rise in obstructive sleep apnea (OSA) in the U.S. over the next three decades, driven by factors such as an aging population and increasing body mass index (BMI) [1][2][3] Group 1: Prevalence Estimates - By 2050, OSA is projected to affect nearly 77 million U.S. adults, a relative increase of nearly 35% from 2020, impacting 46% of adults aged 30-69 [2] - A 65% relative increase in OSA prevalence among women is expected, reaching 30.4 million cases by 2050, highlighting the need for greater awareness of OSA symptoms in women [6] - A 19% relative increase in OSA prevalence among men is anticipated, reaching 45.9 million cases by 2050, indicating ongoing risks in aging male populations [6] Group 2: Health Implications - OSA is linked to serious health issues, including hypertension, cardiovascular disease, diabetes, and stroke, with over 80% of cases remaining undiagnosed and untreated [3] - The study emphasizes the urgent need for earlier diagnosis, preventative strategies, and healthcare resource allocation to address OSA as a major public health concern [3][5] Group 3: Industry Response - The research calls for expanded screening, increased awareness of symptoms, and improved access to testing and treatment, particularly in home settings [4][5] - The anticipated impact of GLP-1 therapies on future OSA prevalence is limited, with reductions estimated at under 5%, indicating that obesity is just one of many contributing factors to OSA [6] - The study serves as a data-driven forecast to help health systems, payers, and policymakers prepare for the growing prevalence of OSA and improve long-term patient outcomes [5][6]

Financial Data and Key Metrics Changes - The company achieved record quarterly revenue of $17.4 million, representing a robust 17% year-over-year growth, bringing net revenues for the year to $64 million, also a record [6][17] - Operating income reached $3 million in Q4, marking a 30% increase year-over-year, with net income of $2.2 million, a 21% increase compared to the same quarter last year [7][8] - The diluted earnings per share increased to $0.25, a 24% increase versus the prior year [8] - Gross profit increased to $50 million, or 78.1% of net revenues, compared to 76.3% in the previous year [19] Business Line Data and Key Metrics Changes - Home Care segment revenue grew 15% year-over-year to $57.3 million, driven by an increase in direct sales representatives and higher net revenues per approval [6][17] - Hospital Surge revenue increased by 60%, while the distributor channel delivered 76% growth [6] - Non-home care business revenue grew 28.8% to $6.7 million, primarily due to increased distributor and hospital revenue [18] Market Data and Key Metrics Changes - The company reported a significant milestone with the addition of its common stock into the Russell 2000 index, which is expected to improve trading liquidity [9] - The company is targeting the large unrecognized market for bronchiectasis treatment, with an estimated 800,000 patients who could benefit from its SmartVest therapy [11] Company Strategy and Development Direction - The company is focused on expanding its direct sales team, ending the year with 55 representatives, up from 53 the previous year, and plans to increase this number to 61 in fiscal year 2026 [9][18] - The company is implementing a manufacturing optimization plan to add new capacity, expected to be completed in early fiscal year 2026 [14][35] - The company is enhancing its Smart Order e-prescribe solution to streamline order submissions and improve efficiency [15][52] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future prospects, expecting to deliver double-digit top-line growth and strong operating cash flows in the upcoming fiscal year [21] - The company is well insulated from tariff-related turbulence, with 99% of revenues generated domestically [13] - Management highlighted the importance of the recent FDA approval of a drug for bronchiectasis, which is expected to raise awareness and potentially benefit the company [30][50] Other Important Information - The company completed a $5 million stock repurchase program in Q4, demonstrating confidence in its future [8] - The company maintained zero back orders in Q4 with a first pass yield of 99% [13] Q&A Session Summary Question: Can you provide more color on the strong margins in the quarter? - Management noted that strong growth in home care revenue, a high-margin channel, and a favorable mix within that channel contributed to the gross margin strength [25] Question: What caused the hospital channel to be so strong? - Management indicated that investments in hospital-focused sales reps and the untapped market dynamics contributed to the growth [27] Question: Are you seeing increased awareness around bronchiectasis due to new entrants in the market? - Management believes that the introduction of new drugs has raised awareness of bronchiectasis, which could serve as a tailwind for the company [30] Question: How does the manufacturing optimization plan expand current capacity? - Management stated that the plan is not primarily a margin play but aims to expand growth opportunities within the existing footprint [35] Question: What has been the response to the new CRM system? - Management reported positive feedback from the sales team, indicating that the new system has improved access to data and productivity [42]

Company to Advance Development of its Patented DeviceLAS VEGAS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products is pleased to provide the following update on the development of its Save A Life (“SAL”) choking rescue device. Odyssey has created a prototype device and now plans to continue the advancement of the product with the ultimate goal of filing a subm ...

Core Viewpoint - Ventripoint Diagnostics Ltd. is conducting a non-brokered private placement to raise up to CDN$500,000 through unsecured convertible debenture units, which will be convertible into common shares and include purchase warrants [1][2]. Group 1: Offering Details - The offering consists of unsecured convertible debenture units, with each unit having a principal amount of $1,000 convertible into common shares at a price of $0.11 per share [1][2]. - Each unit will also include 9,000 common share purchase warrants, allowing the holder to purchase shares at $0.14 until December 31, 2027 [1][2]. - The debentures will mature on December 31, 2027, and will bear an interest rate of 10%, payable semi-annually either in cash or in common shares at a 20-day VWAP market price [3]. Group 2: Use of Proceeds - The proceeds from the offering will be utilized for operational costs related to sales and marketing, hiring additional key personnel, and general working capital purposes [5]. Group 3: Securities and Compliance - All securities issued will be subject to a hold period of four months plus one day from the closing date of the offering, and the offering is subject to approval by the TSXV [6]. - The securities will not be registered under the U.S. Securities Act of 1933 and cannot be offered or sold in the United States without proper registration or exemption [7]. Group 4: Insider Transactions and Other Issuances - The corporation has issued 564,473 common shares to settle $76,203.59 of debenture interest, with shares subject to a hold period [8]. - An insider transaction involved the issuance of 50,042 shares, which is considered a related party transaction under MI 61-101, relying on exemptions due to the transaction's market capitalization not exceeding 25% [9]. - The corporation has also issued 6,000 common shares related to the exercise of broker's warrants and 200,000 options exercised at $0.11, both subject to a hold period [10][11]. Group 5: Advisory Agreement - An advisory agreement with Fournel Advisory includes a total consideration of 265,000 options exercisable at $0.11 per share and a cash payment of USD $30,000 [12]. Group 6: Company Overview - Ventripoint has established itself as a leader in applying AI to echocardiography, with its VMS+ products providing accurate cardiac measurements comparable to MRI, supported by regulatory approvals in the U.S., Europe, and Canada [14].

Company Overview - TransMedics Group, Inc. is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure [3] - The company is headquartered in Andover, Massachusetts, and is recognized as the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation [3] - TransMedics aims to address the unmet need for more and better organs for transplantation through its developed technologies that preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs [3] Upcoming Events - TransMedics will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 10:00 a.m. EST [2] - The company will also present at the Baird 2025 Global Healthcare Conference on September 9, 2025, at 12:15 p.m. EST [2] - A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website [2]

Group 1 - Zimmer Biomet Holdings, Inc. will present at the Annual Morgan Stanley Healthcare Conference on September 8, 2025, at 8:30 a.m. ET [1] - A live webcast of the presentation will be available on Zimmer Biomet's Investor Relations website and will be archived for replay [1] Group 2 - Zimmer Biomet is a global leader in medical technology, focusing on maximizing mobility and improving health through innovative products and integrated digital and robotic technologies [2] - The company leverages data, data analytics, and artificial intelligence to enhance the patient experience [2] Group 3 - With over 90 years of experience, Zimmer Biomet is committed to delivering high-quality solutions to patients and providers [3] - The company emphasizes a culture of evolution and innovation in its operations [3] Group 4 - Zimmer Biomet operates in over 25 countries and has sales in more than 100 countries [4]

Core Insights - Johnson & Johnson's stock has increased over 23% year-to-date, indicating strong investor confidence despite ongoing legal challenges [1] - The strategic separation of its consumer health division has transformed Johnson & Johnson into a more agile company focused on high-margin, high-growth sectors [2][3] - The company is now dedicated to innovative medicine and medical technology, moving away from legacy lawsuit risks towards a clearer growth path [3] Financial Performance - The 2023 spinoff of the consumer health business, now Kenvue, has allowed Johnson & Johnson to focus on pharmaceuticals and MedTech, enhancing shareholder value [4] - In Q2 2025, total revenues reached $23.74 billion, with Innovative Medicine contributing $15.20 billion and MedTech $8.54 billion [5] - Management raised its full-year sales guidance by $2 billion, reflecting a sharpened focus on high-return opportunities [6] Pharmaceutical Division Strength - Johnson & Johnson's pharmaceutical division is robust, with a strong portfolio of drugs offsetting anticipated challenges [7] - The oncology franchise saw a remarkable 22.3% operational sales growth in Q2, driven by successful products like Darzalex and Carvykti [12] - The company is managing the transition of Stelara effectively, with its successor Tremfya growing 30.1% [12] MedTech Division Growth - The MedTech division achieved 6.1% operational growth in Q2, with the cardiovascular business expanding by 22% [9] - Recent acquisitions, such as Abiomed and Shockwave Medical, are exceeding expectations and establishing Johnson & Johnson as a leader in high-growth cardiovascular markets [10] Future Growth Potential - Johnson & Johnson's late-stage pipeline indicates a clear path to future revenue, with the FDA granting Priority Review for TAR-200 and a recent application for icotrokinra [12] - The company's M&A strategy adds diversification and financial strength, supporting long-term liabilities while maintaining innovation [11] Investment Appeal - Johnson & Johnson is trading at a forward P/E ratio of 16.88, offering a blend of growth potential and financial stability [13] - The company has a strong dividend history, with a yield of 2.91% and a sustainable payout ratio of 55.6% of earnings, indicating safety and room for growth [18]

Core Insights - Stryker Corporation (SYK) reported strong second-quarter 2025 results with net sales increasing by 11.1% year over year to $6.1 billion and organic sales improving by 10.2% [1] - Adjusted earnings per share (EPS) of $3.13 surpassed consensus estimates, driven by healthy volume growth, favorable pricing, and disciplined execution [1][2] - Management raised full-year organic sales growth guidance to 9.5-10% and adjusted EPS to $13.40-$13.60 [2] Short-Term Growth Drivers - The Orthopaedics segment showed strong performance, with knee implants growing by 6.3% and hip implants advancing by 8.9%, supported by rising elective procedure volumes and Mako robotic platform adoption [3][4] - Mako procedures reached a milestone of 2 million, with significant momentum in international markets as hospitals scale robotic-assisted surgery capabilities [4] - The MedSurg and Neurotechnology segments reported 16.7% organic growth, driven by high demand for patient handling, surgical instruments, and neurovascular solutions [5] Long-Term Growth Drivers - Stryker's international business is a key growth lever, with double-digit gains in Asia-Pacific and Latin America, and investments in localized manufacturing and R&D to capture market share [8] - The innovation pipeline remains robust, with R&D spending above 6% of sales, focusing on expanding the Mako platform and upcoming launches in sports medicine and endoscopy [9] - Recent acquisitions in spine and neurovascular markets are yielding integration synergies and enhancing Stryker's competitive position [10][11] Challenges - Competitive pressures in robotic orthopaedics are intensifying, with major competitors advancing rival platforms, necessitating continued evidence of superior outcomes [14] - Macro pressures such as persistent inflation, foreign exchange volatility, and wage pressures are impacting margins, despite strong top-line growth [15][16] - Supply-chain reliability has improved, but ongoing bottlenecks in electronic components and regulatory hurdles for product approvals remain risks [17] Competitors' Update - Zimmer Biomet reported net sales of approximately $2.08 billion, up 7% year over year, and raised its full-year EPS guidance to $8.10–$8.30 [18] - Johnson & Johnson's sales reached $23.7 billion, marking a 5.8% year-over-year increase, with a raised full-year sales forecast [19] - Medtronic's revenues were roughly $8.58 billion, reflecting an 8.3% year-over-year increase, and it raised its full-year organic revenue growth and EPS guidance [20] Conclusion - Stryker's second-quarter performance reflects strong execution across its core segments, with a robust pipeline and global expansion supporting long-term growth [21] - However, premium valuation, competitive intensity, and macro risks temper the near-term investment outlook [21]